Huatuo Zaizao Pills
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ischemic Stroke
Conditions
Ischemic Stroke
Trial Timeline
Dec 1, 2012 → Dec 1, 2014
NCT ID
NCT01758536About Huatuo Zaizao Pills
Huatuo Zaizao Pills is a approved stage product being developed by Guangzhou Baiyunshan Pharmaceutical Holdings for Ischemic Stroke. The current trial status is unknown. This product is registered under clinical trial identifier NCT01758536. Target conditions include Ischemic Stroke.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01758536 | Approved | UNKNOWN |
Competing Products
20 competing products in Ischemic Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 23 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 33 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Approved | 85 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 41 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 65 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 52 |
| Statin | Shionogi | Approved | 85 |
| fospropofol + propofol | Eisai | Phase 2 | 52 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 52 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 52 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Repatha | Amgen | Approved | 84 |